Generic LUTETIUM LU-177 DOTATATE INN entry, drug patent expiration information and freedom to operate

Sponsor	Phase
RayzeBio, Inc.	PHASE1
Joshua Palmer	PHASE1
Emory University	PHASE1

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUTATHERA	Injection	lutetium lu-177 dotatate	10 mCi/mL	208700	1	2023-11-13

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aaa Usa Inc	LUTATHERA	lutetium lu-177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018	AP	RX	Yes	Yes	12,168,063*PED	⤷ Start Trial			Y	⤷ Start Trial
Aaa Usa Inc	LUTATHERA	lutetium lu-177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Aaa Usa Inc	LUTATHERA	lutetium lu-177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018	AP	RX	Yes	Yes	11,904,027*PED	⤷ Start Trial			Y	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Argentina	119655		⤷ Start Trial
Australia	2018433575		⤷ Start Trial
Australia	2022203683		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
4095130	202440024	Slovenia	⤷ Start Trial	PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; NATIONAL AUTHORISATION NUMBER: EU/1/22/1703; DATE OF NATIONAL AUTHORISATION: 20221209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
4095130	2490022-7	Sweden	⤷ Start Trial	PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130	CA 2024 00027	Denmark	⤷ Start Trial	PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Last updated: November 7, 2026

Lutetium Lu-177 dotatate, marketed as Lutathera by Novartis, is the commercial leader in peptide receptor radionuclide therapy for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The product has moved from a specialty oncology launch to a roughly $1 billion annual franchise, supported by expanded treatment adoption, global reimbursement, and Novartis' radioligand manufacturing infrastructure. Its main risks are manufacturing capacity, radiation-handling requirements, competition from other radioligand therapies, and eventual loss of regulatory exclusivity.

What is the FDA status of lutetium Lu-177 dotatate?

The FDA approved Lutathera on January 26, 2018, under NDA 208700. The approved indication covers adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut tumors.[1]

Regulatory milestone	Date
EMA approval	September 2017
FDA approval	January 26, 2018
FDA application	NDA 208700
Dosage	7.4 GBq intravenously every eight weeks
Standard treatment course	Four administrations
Required co-therapy	Long-acting octreotide
Regulatory category	Orphan drug and new molecular entity

Lutathera is administered with renal-protection amino acids and requires radiation-safety controls. The product is not a conventional oral or injectable small-molecule therapy. Its commercial delivery depends on nuclear pharmacies, licensed treatment centers, isotope supply, specialized shipping, and coordinated patient scheduling.

The FDA approval was based principally on NETTER-1, a randomized Phase 3 study in patients with advanced midgut neuroendocrine tumors. Lutathera reduced the risk of progression or death compared with high-dose octreotide LAR. The treatment produced a clinically meaningful progression-free-survival advantage and established PRRT as a standard option for appropriate patients.[1]

How large is the lutetium Lu-177 dotatate market?

The addressable market is concentrated but commercially attractive. Gastroenteropancreatic neuroendocrine tumors are less prevalent than major solid tumors, yet treatment duration, specialist dependence, and limited alternatives support premium pricing.

Market growth is driven by five factors:

Increased diagnosis of neuroendocrine tumors through improved imaging and pathology.
Greater use of gallium-68 somatostatin receptor imaging to identify eligible patients.
Earlier referral to specialist neuroendocrine tumor centers.
Expansion of PRRT capacity outside the United States and Western Europe.
Increased physician familiarity following the commercial launch of Novartis' second radioligand therapy, Pluvicto.

Lutathera competes within a broader treatment sequence that includes somatostatin analogs, targeted agents, chemotherapy, liver-directed therapy, surgery, and radioligand therapy. Its strongest position is in patients with somatostatin receptor-positive disease who have progressed on somatostatin analog therapy.

Market positioning by treatment class

Treatment class	Representative products	Relationship to Lutathera
Somatostatin analogs	Octreotide LAR, lanreotide	Earlier-line disease control and hormonal symptom management
Targeted therapies	Everolimus, sunitinib	Alternative systemic treatment depending on tumor type
Chemotherapy	CAPTEM and other regimens	More relevant in selected pancreatic and aggressive tumors
PRRT	Lutathera	Established radioligand option for SSTR-positive GEP-NETs
Other radioligand therapy	Investigational Lu-177 and Ac-225 agents	Future competitive risk
Liver-directed therapy	Embolization, ablation, radioembolization	Used for liver-dominant disease

What are Lutathera sales and financial trajectory?

Novartis has reported rapid, sustained growth for Lutathera since launch. The product benefits from a high-value treatment course and increasing treatment-center capacity.

Fiscal year	Reported Lutathera sales	Approximate year-over-year change
2022	Approximately $650 million	High-teens to low-twenties percentage growth
2023	Approximately $850 million	Approximately 25% to 30%
2024	Approximately $1.0 billion	Approximately 20% to 25%

Sources: Novartis annual reports and full-year financial disclosures.[2-4]

The financial trajectory reflects volume expansion more than price increases. The principal commercial variables are:

Number of qualified treatment centers.
Availability of Lu-177 isotope.
Patient identification through SSTR imaging.
Reimbursement approval and treatment-center throughput.
Use across the full approved treatment course.
Geographic expansion in Europe, Asia-Pacific, and other specialty markets.

The product is strategically important because it shares infrastructure with Novartis' radioligand portfolio. Lutathera contributes recurring demand for isotope procurement, radiochemistry, specialized manufacturing, and distribution. It also gives Novartis commercial access to nuclear-medicine centers that can support Pluvicto and future radioligand products.

Lutathera's sales growth rate should moderate as the largest specialist centers mature and the product approaches broader market penetration. Growth can continue through geographic expansion and increased use in earlier treatment lines, but those opportunities depend on clinical evidence and local treatment guidelines.

When does Lutathera lose exclusivity?

Lutathera's regulatory exclusivity is more important than a single patent expiration date.

Regulatory exclusivity

The product received U.S. orphan-drug exclusivity. The seven-year orphan exclusivity period began on the FDA approval date and ran to January 26, 2025, subject to the statutory limitations applicable to orphan products.[1]

Orphan exclusivity prevents FDA approval of the same drug for the same orphan indication during the exclusivity period, with statutory exceptions. It does not prevent all competing products, off-label use, or development of a different drug with a different active moiety.

The FDA's chemical-entity exclusivity period is four years from approval. That period expired before the orphan exclusivity period. Any pediatric exclusivity, if granted, would extend applicable exclusivity periods by six months; no pediatric extension is assumed in the base timeline.

Patent exclusivity

Lutathera is protected by a network of patents relating to radiolabeled somatostatin analogs, formulations, preparation methods, and use in oncology. Patent expiration varies by jurisdiction and patent family. The practical loss-of-exclusivity date therefore depends on:

Whether a patent is listed for NDA 208700.
Whether a challenger raises invalidity or noninfringement arguments.
Patent-term adjustment or extension.
The scope of the asserted claims.
Regulatory approval of a competing Lu-177 dotatate product.
Commercial access to isotope and radiopharmacy infrastructure.

Public patent databases identify patent families covering radiolabeled somatostatin analogs and associated manufacturing technology, including U.S. patents assigned to Advanced Accelerator Applications and related Novartis entities. A patent expiry date for one family does not establish generic entry because other formulation, process, use, or regulatory barriers may remain.[5]

What patents protect lutetium Lu-177 dotatate?

The patent estate generally falls into four technical groups.

Active pharmaceutical ingredient and radiolabeled analog patents

These patents cover complexes of lutetium-177 with somatostatin analogs, including compounds structurally related to dotatate. Claims may cover the chelator-peptide complex, radionuclide conjugates, or specific radiolabeled compositions.

Formulation patents

Formulation claims may cover the finished radiopharmaceutical, stabilizers, buffering systems, metal-complexing conditions, isotonicity, and injectable compositions. These claims can be commercially important because radiopharmaceuticals are sensitive to radiolysis and must remain within defined radiochemical purity specifications.

Manufacturing patents

Manufacturing claims may address:

Chelation of Lu-177 to the peptide.
Purification of the radiolabeled product.
Removal of unbound radionuclide.
Sterile filtration and aseptic filling.
Stability control during radioactive decay.
Kit-based or centralized production methods.

Manufacturing claims can impose a practical barrier even when composition claims are vulnerable. A competitor may need a noninfringing process that still meets radiochemical purity, sterility, dose calibration, and shipping requirements.

Method-of-use patents

Method-of-use claims may cover treating SSTR-positive neuroendocrine tumors with defined dosing schedules, patient-selection criteria, or combinations with somatostatin analogs. Their strength depends on claim construction and whether the relevant treatment protocol is sufficiently specific.

What is the Orange Book status of Lutathera?

Lutathera is listed in the FDA Orange Book under NDA 208700. The Orange Book is the relevant source for determining listed patents, pediatric exclusivity, and generic regulatory pathways.[6]

For a radiopharmaceutical, Orange Book analysis has limits. A listed patent may not cover every technically feasible competitor. Conversely, an unlisted manufacturing or process patent may still create litigation or operational risk outside the standard ANDA patent-certification framework.

The relevant generic pathways include:

An ANDA for a product determined to be therapeutically equivalent.
A 505(b)(2) application relying partly on FDA findings for Lutathera.
A full NDA for a materially different radioligand product.
A biosimilar pathway, which is not applicable because Lutathera is a chemically defined radiopharmaceutical rather than a biologic.

Are there Paragraph IV challenges to Lutathera?

A Paragraph IV challenge would require a generic applicant to certify that a listed patent is invalid, unenforceable, or not infringed. Publicly visible litigation has not established a major, commercially consequential Paragraph IV challenge to Lutathera comparable to challenges involving high-volume oral medicines.

The absence of a prominent challenge is consistent with the product's market structure:

The eligible patient population is specialized.
Manufacturing requires radioactive isotope handling.
Distribution is time-sensitive because Lu-177 decays.
Treatment requires certified centers.
Product economics may not support multiple generic suppliers.
A 505(b)(2) or full NDA strategy may be more practical than a conventional ANDA.

A future challenger could target composition, formulation, or method-of-use patents. The most credible entry route would likely involve a technically differentiated radiolabeled somatostatin analog or a noninfringing manufacturing process rather than a simple copy distributed through ordinary pharmaceutical wholesalers.

Which companies are challenging Lutathera commercially?

No company currently matches Novartis' integrated position in approved PRRT for GEP-NETs. Competition is divided between established therapies and pipeline radioligands.

Established competitive pressure

Pluvicto, also marketed by Novartis, is the most important adjacent product. It targets prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer rather than SSTR-positive neuroendocrine tumors. The products do not directly substitute for one another, but they compete for:

Lu-177 supply.
Radiopharmacy capacity.
Nuclear-medicine staff.
Treatment-center capital.
Patient scheduling slots.
Hospital budget and reimbursement resources.

Other competitors include advanced somatostatin analogs, everolimus, sunitinib, chemotherapy, and liver-directed procedures.

Pipeline radioligand competition

Potential future competition includes:

Lu-177-labeled somatostatin receptor agonists and antagonists.
Actinium-225 somatostatin receptor therapies.
Alpha-emitting radionuclides.
Improved chelators and peptide constructs.
Combination radioligand regimens.
Products designed for higher tumor uptake or reduced renal and marrow toxicity.

These agents must demonstrate clinical benefit, acceptable radiation exposure, scalable isotope supply, and a workable treatment-center model. A technically superior molecule will not automatically displace Lutathera if its isotope supply is unreliable.

How strong is the Lutathera patent estate?

The patent estate is commercially meaningful but not impenetrable.

Estate component	Relative strength	Commercial assessment
Core radiolabeled compound	High to moderate	Central to product identity but exposed to prior-art and claim-scope challenges
Finished formulation	Moderate	Can delay direct substitution if claims cover essential excipients or stability conditions
Manufacturing process	Moderate to high	Important where competitors cannot easily reproduce sterile, high-purity production
Method of use	Moderate	Value depends on treatment protocol and enforceability
Regulatory exclusivity	Expired in the United States as of January 2025	No longer the primary U.S. barrier
Supply-chain control	High practical importance	May exceed patent strength for near-term market entry

The strongest barrier is the combination of intellectual property and operational complexity. A competitor must secure isotope, produce a compliant sterile radiopharmaceutical, distribute it within the decay window, obtain regulatory approval, and establish treatment-center access.

What manufacturing and supply barriers affect Lutathera?

Lutetium-177 supply is a central market variable. Production depends on reactor or accelerator capacity, enriched ytterbium or other target materials, isotope separation, quality control, and international logistics.

Commercial constraints include:

Radioactive decay during transportation.
Limited availability of qualified manufacturing sites.
Short shelf life relative to conventional medicines.
Need for specialized packaging and dose calibration.
Regulatory controls for radioactive materials.
Dependence on nuclear pharmacies and hospital infrastructure.
Competition with Pluvicto and investigational Lu-177 products.

Novartis has expanded radioligand manufacturing capacity through investments in sites and supply-chain partnerships. The company also acquired Advanced Accelerator Applications, the original Lutathera developer, strengthening control over the product's technology and production network.[7]

What litigation and settlement risks affect Lutathera?

The public commercial risk from patent litigation remains lower than for many mass-market drugs because the product has a narrow patient population and complex production model. Litigation risk would increase if:

A generic or 505(b)(2) applicant files for approval.
Novartis lists additional patents or asserts process claims.
A rival radioligand obtains a competing indication.
A supplier or manufacturing partner develops a competing product.
Treatment-line expansion materially increases revenue exposure.

A settlement could involve a delayed launch date, geographic carve-outs, royalty terms, or restrictions on the approved indication. No major public settlement has defined Lutathera market entry as of the latest broadly available company and court disclosures.

How does Lutathera compare with Pluvicto?

Metric	Lutathera	Pluvicto
Active radioligand	Lu-177 dotatate	Lu-177 vipivotide tetraxetan
Target	Somatostatin receptor	PSMA
Main disease	GEP-NETs	Metastatic prostate cancer
FDA approval	2018	2022
Patient population	Smaller and specialist-led	Larger oncology market
Commercial maturity	Established franchise	Faster-growth launch product
Key shared risk	Lu-177 supply and treatment-center capacity	Lu-177 supply and treatment-center capacity
Strategic role	Established PRRT platform	Major growth driver for Novartis radioligand therapy

Pluvicto has a larger potential market, but Lutathera has longer commercial experience and a more established treatment pathway. Together, the products support Novartis' position in radioligand therapy and create scale advantages in isotope sourcing, manufacturing, regulatory operations, and center activation.

What generic launch scenarios exist for Lutathera?

Base case: controlled erosion after patent clearance

The most likely base case is gradual competitive entry rather than an abrupt price collapse. One or more competitors could enter after regulatory and patent barriers weaken, but limited treatment-center capacity and isotope supply would constrain share capture.

Upside case: continued protected growth

Lutathera can sustain growth if patient diagnosis increases, PRRT moves earlier in treatment, and Novartis expands manufacturing capacity. Label expansion or favorable comparative data would improve the trajectory.

Downside case: radioligand substitution

A rival product could reduce Lutathera demand if it demonstrates better tumor response, lower renal or marrow toxicity, fewer treatment visits, or easier manufacturing. Alpha-emitting products could be particularly disruptive if isotope supply and safety profiles become manageable.

What is the geographic coverage of Lutathera?

Lutathera has regulatory and commercial presence in the United States, European markets, and other countries where radiopharmaceutical infrastructure supports PRRT. Geographic growth is uneven because approval does not guarantee treatment access.

The strongest markets are those with:

Specialist neuroendocrine tumor centers.
SSTR imaging availability.
Nuclear-medicine physicians and trained staff.
Reimbursement for radiopharmaceutical therapy.
Licensed radioactive-material handling.
Reliable isotope distribution.

Emerging-market expansion is constrained by center qualification, reimbursement, and supply-chain requirements rather than by clinical demand alone.

Key Takeaways

Lutetium Lu-177 dotatate is the established PRRT product for SSTR-positive GEP-NETs.
FDA approval occurred on January 26, 2018, under NDA 208700.
U.S. orphan-drug exclusivity ended on January 26, 2025.
Novartis Lutathera sales increased from roughly $650 million in 2022 to approximately $1 billion in 2024.
The product's principal barriers are radioligand manufacturing, isotope supply, treatment-center capacity, and specialized distribution.
Lutathera is not a biosimilar opportunity. Potential competitors are more likely to pursue 505(b)(2), full NDA, or differentiated radioligand strategies.
Patent protection covers radiolabeled compounds, formulations, manufacturing methods, and methods of use, with expiration varying by family and jurisdiction.
Pluvicto is the main adjacent commercial competitor for manufacturing capacity and nuclear-medicine infrastructure, although it treats a different cancer.
Revenue erosion is likely to be gradual unless a competing radioligand shows materially better efficacy, safety, or operational convenience.

FAQs about lutetium Lu-177 dotatate

Is Lutathera a biologic or a small-molecule generic opportunity?

Lutathera is a chemically defined radiopharmaceutical, not a biologic. A future competitor would generally pursue an ANDA, 505(b)(2), or full NDA strategy rather than a biosimilar application.

How long does a Lutathera treatment course last?

The standard course consists of four intravenous administrations given at eight-week intervals, subject to clinical management and dose adjustments.

Does Lutathera compete directly with Pluvicto?

No. Lutathera targets somatostatin receptors in neuroendocrine tumors, while Pluvicto targets PSMA in prostate cancer. They compete indirectly for Lu-177 supply, manufacturing capacity, and nuclear-medicine treatment centers.

What is the main commercial risk to Lutathera revenue?

The main risk is substitution by a competing radioligand with better efficacy, safety, dosing convenience, or supply reliability. Conventional generic entry is a secondary risk because radioactive manufacturing and distribution are complex.

Can Lutathera sales continue growing after U.S. orphan exclusivity expires?

Yes. Sales can continue to grow through market expansion, increased PRRT adoption, geographic penetration, and earlier-line use. Loss of orphan exclusivity increases potential competition but does not itself create immediate commercial substitution.

References

U.S. Food and Drug Administration. (2018). FDA approves Lutathera for treatment of certain gastroenteropancreatic neuroendocrine tumors. FDA.
Novartis AG. (2023). Annual report 2022. Basel, Switzerland: Novartis.
Novartis AG. (2024). Annual report 2023. Basel, Switzerland: Novartis.
Novartis AG. (2025). Annual report 2024. Basel, Switzerland: Novartis.
United States Patent and Trademark Office. (n.d.). Patent Center and patent search records for radiolabeled somatostatin analogs. Washington, DC: USPTO.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
Novartis AG. (2018). Novartis completes acquisition of Advanced Accelerator Applications. Basel, Switzerland: Novartis.

Recent Clinical Trials for LUTETIUM LU-177 DOTATATE

Paragraph IV (Patent) Challenges for LUTETIUM LU-177 DOTATATE